Abeona Therapeutics (ABEO) Depreciation & Amortization (CF) (2011 - 2026)

Abeona Therapeutics' Depreciation & Amortization (CF) history runs 16 years deep, the most recent figure standing at $690000.0 for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) rose 29.21% year-over-year to $690000.0; the TTM figure through Mar 2026 stood at $2.7 million (up 32.14% YoY), while the FY2025 annual figure was $2.5 million, up 27.2% from the prior year.
• Depreciation & Amortization (CF) was $690000.0 for Q1 2026 at Abeona Therapeutics, down from $863000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $863000.0 in Q4 2025 to a low of $487000.0 in Q2 2024.
• Historically, Depreciation & Amortization (CF) has averaged $624941.2 across 5 years, with a median of $608000.0 in 2025.
• The sharpest annual moves came in 2022 and 2023: Depreciation & Amortization (CF) jumped 4775.0% in 2022, then slumped 33.21% in 2023.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $729000.0 in 2022, then plunged by 32.65% to $491000.0 in 2023, then increased by 9.78% to $539000.0 in 2024, then soared by 60.11% to $863000.0 in 2025, then slipped by 20.05% to $690000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $690000.0 (Q1 2026), $863000.0 (Q4 2025), and $608000.0 (Q3 2025), per Business Quant data.